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the care: 78% recommend swimming; 68% regular walks; 55%
yoga; 27% stretching and 23% bicycling. CONCLUSIONS:
FMS is a frequently diagnosed illness in general medicine (6 FMS
patients/GP). The difﬁculties in treating the illness seem evident
as shown by the multiple therapeutic choices. We may note the





RELATIONSHIPS BETWEEN AGE, NUMBER OF
PRESCRIPTIONS,AND CO-MORBIDITIES AMONG VA
PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA
OBJECTIVE: To determine the relationship between the Charl-
son co-morbidity index and age and annual number of pre-
scriptions dispensed among a sample of Veterans Affairs 
(VA) patients receiving nonsteroidal anti-inﬂammatory agents
(NSAIDs). METHODS: NSAID patients treated at three VA
medical centers were identiﬁed from a previous study. Prescrip-
tion records, demographics, and International Classiﬁcation of
Disease-9 (ICD-9) diagnoses were obtained from the VA elec-
tronic databases. The comorbidity index for each patient was
determined by applying appropriate weights to ICD-9 diagnoses
and summing the weights for each patient. We applied stepwise
regression with co-morbidity index as the dependent variable
and age and number of prescriptions as independent variables.
We used VA-1 as the pilot study, to determine if a relationship
existed between the variables. We performed the same analyses
using the additional two medical centers to validate the rela-
tionship. RESULTS: There were 17,893 patients included in the
study, 7322 at VA-1, 6094 at VA-2, and 4447 at VA-3. Mean
ages ± standard deviations (SD) were 59.5 ± 13.3, 58.4 ± 13.0,
and 62.5 ± 13.1, respectively. Mean annual numbers of pre-
scriptions (±SD) were 33.6 ± 31.7, 31.8 ± 29.9, and 47.9 ± 39.5,
respectively. Mean comorbidity weights (±SD) were 2.1 ± 2.4,
1.5 ± 2.1, and 1.6 ± 1.9, respectively (p < 0.001). Stepwise regres-
sion results, with comorbidity as the dependent variable, were
signiﬁcant (p < 0.001) for age and number of prescriptions and
explained 20.2%, 16.7%, and 14.4% of the variance. When data
were combined and VA medical center was included, the model
explained 18.8% of the variance (p < 0.001 for medical center,
age and number of prescriptions). The adjusted mean comor-
bidity weights by VA medical center were 2.2 (standard error
(SE) = 0.023), 1.6 (SE = 0.25) and 1.3 (SE = 0.30) respectively.
CONCLUSION: Among VA NSAID patients, the annual
number of prescriptions, medical center, and age are strongly
related to the Charlson co-morbidity index.
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CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED
TO PREDICT FUTURE RISK OF NSAID-INDUCED
GASTROINTESTINAL EVENTS
Livengood K,Ambegaonkar A, Craig T
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: The objective of this study is to cross-validate a
new questionnaire designed to predict the future risk of NSAID-
induced gastrointestinal events against a standard questionnaire,
the GI SCORE survey. METHODS: Four-hundred consenting,
consecutive patients from a rheumatology clinic in the mid-
western United States were administered both questionnaires.
The questionnaires were not administered in any particular
order. The new questionnaire contains questions that are similar
to ﬁve of six questions found in GI SCORE, in addition to ﬁve
questions not found in GI SCORE. The completed GI SCORE
questionnaires were scored and the associated risk levels were
determined. Feasible generalized least squares (FGLS) and multi-
nomial logistic (MNL) regression were used to map the ques-
tions from the new questionnaire onto the scores and two
different groups of risk levels, respectively, determined from GI
SCORE. Based on the results of the FGLS analysis, a scoring
scheme was created for the new questionnaire, allowing the pre-
diction of risk levels similar to GI SCORE. Risk levels generated
from both FGLS and MNL were compared to those predicted
by GI SCORE. RESULTS: For FGLS, the new questionnaire pre-
dicted risk levels that matched those predicted by GI SCORE
with 83% accuracy. When the original 4 risk levels predicted by
GI SCORE were collapsed into 3 risk levels, with the 2 most
severe risk levels becoming a single risk level, the predictions
from the new questionnaire were 89% accurate. For MNL, the
new questionnaire was 76% and 87% accurate for four and
three risk levels, respectively. CONCLUSIONS: The new ques-
tionnaire appears to be reasonably accurate in predicting the
same risk as those predicted by a standard survey. FGLS is
slightly more accurate than MNL in predicting risk for both
groups of risk considered.
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COST-UTILITY OUTCOMES SIMULATION MODEL FOR
OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA)
PATIENTS (COSMO): DEVELOPMENT AND VALIDATION OF A
PHARMACOECONOMIC MODEL
Niculescu L1, Lising AW2, Neumann PJ3
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3Harvard School of Public Health, Boston, MA, USA
OBJECTIVE: To construct a ﬂexible and transparent pharma-
coeconomic model to assess the value of COX-2 selective
inhibitors (COX-2s) in the treatment of arthritis. METHODS:
Literature searches and interviews with Health Care practition-
ers were conducted to identify critical issues for model con-
struction. Model assumptions and parameters estimates for the
new COSMO model were made based on these efforts. Conver-
gent validity was assessed by comparing COSMO model outputs
to results obtained using previously published models, when
similar inputs were used in each model. RESULTS: Because
arthritis patients often switch medications, the COSMO model
simulates treatment strategies, rather than individual drugs.
COSMO allows users to compare strategies under which patients
start on an NSAID or COX-2 and switch medications twice. It
was structured as a one-month cycle Markov model with the fol-
lowing disease states: GI discomfort, loss of efﬁcacy, complicated
ulcer, uncomplicated ulcer, CV event, no events, and death.
Inputs allowed for different levels of complexity to address the
difﬁculty in obtaining data sources in different countries. Multi-
ple clinical (number of deaths, GI discomfort, ulcers, uncon-
trolled arthritis) and economic (drug costs, costs of managing GI
and CV events, total costs) outputs were included. Monte Carlo
simulations, acceptability curves, cost-effectiveness planes and
extensive univariate and multi-variate sensitivity analysis can be
performed with any input. For base case analyses, we assume a
3rd party payer perspective. In the validation exercise, we
applied inputs from a published model (Maetzel et al., 2003),
and obtained similar results (7% variation) and similar trends 
in sensitivity analyses, suggesting strong convergent validity.
CONCLUSIONS: COSMO is a pharmacoeconomic model 
that assesses the value of different treatment strategies for
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osteoarthritis and rheumatoid arthritis. From a third party per-
spective, this model allows customization with respect to clini-
cal and cost inputs, as well as treatment patterns.
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ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR
RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY
(WTP) STUDY IN SPANISH PATIENTS
Badia X1, Serrano D1, Magaz S2
1Health Outcomes Research Europe Group, Barcelona, Spain; 2Health
Outcomes Policy and Economics, Barcelona, Spain
OBJECTIVES: One of the main treatment goals in rheumatoid
arthritis (RA), for which there is no curative treatment so far, is
to improve Health Related Quality of Life (HRQoL) and patient
satisfaction with treatment. The Willingness to pay (WTP)
method can be used as a tool to assess patient preferences and
the perceived value of non-marketed goods intangible goods.
Although the efﬁcacy of adalimumab and inﬂiximab in the treat-
ment of RA might be the same, the differences in administration
route and dosage might impact patient preferences and perceived
value of the drugs. METHODS: We carried out a WTP study in
RA patients, currently treated with inﬂiximab, assessing patient’s
WTP in the open-ended with follow-up format. We presented a
new treatment, adalimumab, with the same efﬁcacy as inﬂiximab
but with some differential attributes, mainly the possibility to
self-administer the subcutaneous injection, administration at
home, minor time for administration, ergonomic design for being
self-administrating, and ﬁnally presentation just for being used.
RESULTS: In total, 91 patients were included in the study, of
which 76 (83.5%) were WTP for the new treatment. The mean
WTP was 103.4€ per month, which represents the 9% of the
patient’s monthly rent. Patients with poorest health states pre-
sented the lowest monthly WTP as compared with those with
the best-perceived health state (83€ vs. 121€). No differences
were found in the WTP according to other sociodemographic or
clinical variables. CONCLUSIONS: The new treatment is pre-
ferred by most of AR patients, mainly due to the reduced admin-
istration time, which drives a willingness to pay of 9% of the




COST-EFFECTIVENESS OF APREPITANT GIVEN WITH
STANDARD ANTIEMETICS IN PATIENTS RECEIVING
CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY
Ehlken B1, Ihbe-Hefﬁnger A2, Bernard R2, Berger K3, Pellissier JM4,
Deuson R5
1MERG, Medical Economics Research Group, Munich, Germany;
2Klinikum rechts der Isar,Technische Universität München, Munich,
Germany; 3MERG Medical Economics Research Group, Munich,
Germany; 4Merck Research Laboratories, St. Charles, IL, USA; 5Merck
& Co., Inc, Whitehouse Station, NJ, USA
OBJECTIVE: To evaluate from the payer’s perspective the cost-
effectiveness of adding the NK1 receptor antagonist aprepitant
to ondansetron/dexamethasone in patients undergoing highly
emetogenic chemotherapy in ofﬁce-based settings in Germany.
METHODS: We compared aprepitant in combination with
ondansetron/dexamethasone to ondansetron/dexamethasone
alone over a single chemotherapy cycle. To that end a decision-
analytic model based on clinical results and resource utilization
observed in aprepitant Phase III trials was constructed. Health
outcomes included complete response (no emesis, no rescue
therapy) and quality-adjusted life years (QALYs). Utility values
were obtained from the literature. German tariffs and prices were
used to cost health care resources. A series of sensitivity analy-
ses was conducted. RESULTS: In the aprepitant group (N = 514)
68% of the patients were complete responders over the entire
chemotherapy cycle compared to 48% in the standard care
group (N = 518). More patients were emesis-free over the entire
chemotherapy cycle with aprepitant regimen (72%) compared to
standard regimen (49%). Cost difference between aprepitant
regimen and standard therapy was 37€, with 43% of the aprepi-
tant drug cost being offset by lower resource use in the aprepi-
tant group. Incremental cost per QALY gained with aprepitant
was 21,764€. Results were most sensitive to costs of hospital-
izations and rescue medications. CONCLUSIONS: Signiﬁcantly
more patients were estimated being emesis-free when adding
aprepitant to antiemetic standard therapy, with a signiﬁcant pro-
portion of the cost of aprepitant being offset. Use of aprepitant
in ofﬁce-based settings in Germany proved to be cost-effective.
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COST-EFFECTIVENESS OF IMATINIB (GLEEVEC) AS 
FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA
(CML)
El Ouagari K1,Talbot W1, Baladi JF2
1Novartis Pharmaceuticals, Dorval, QC, Canada; 2Novartos
Pharmaceuticals, Florham Park, NJ, USA
OBJECTIVES: To assess the incremental cost-effectiveness of
imatinib relative to interferon alfa plus low-dose cytarabine
(IFN+LDAC) as 1st-line therapy for patients newly diagnosed
with chronic phase CML. METHODS: An economic simulation
model was developed using Microsoft Excel to estimate lifetime
costs, survival and quality-adjusted survival. Data collected in
the International Randomized Interferon vs. STI571 Study (IRIS)
and supplemental data from the literature were used to populate
the model. Patients initially treated with imatinib could switch
to IFN+LDAC and vice-versa for patients started on IFN+LDAC,
with both arms eventually switching to hydroxyurea as 3rd-line
treatment. Long-term survival was modeled on complete cyto-
genetic response (CCyR) after 2 years. Published survival curves
for patients with or without complete CCyR after treatment with
interferon alfa were used to estimate long-term survival.
RESULTS: The results of our cost-effectiveness model showed
that patients treated 1st-line with imatinib were projected to live
for approximately 15.13 years while those treated 1st-line with
IFN+LDAC were projected to live for approximately 10.75
years. Undiscounted lifetime costs were estimated at approxi-
mately $456,000 for patients receiving imatinib and $286,194
for patients receiving IFN+LDAC. After applying a 5% discount
rate, the incremental gain in survival was estimated at 2.09 life-
year and 1.91 quality adjusted life-year in favour of imatinib.
Due to the increased survival, the incremental discounted life-
time costs were approximately $96,118 higher among patients
treated with imatinib, resulting in cost-effectiveness ratios of
Can$45,537/LY saved and Can$49,953/QALY. Assumptions
that affected duration or costs of the treatments had the largest
impact on the ICERs. CONCLUSIONS: Our analysis showed
that imatinib offers both longevity and quality of life beneﬁts.
Furthermore, compared to IFN+LDAC, imatinib proved to be a
cost-effective 1st-line therapy for patients with newly diagnosed
chronic phase CML.
